AUS
NZ
UK
CA
USA
IND
Highlights
- Prasinezumab demonstrates potential to slow motor progression in early-stage Parkinson's disease.
- Subgroup analysis of levodopa-treated patients shows significant improvement with prasinezumab.
- Prothena aims for first-in-class disease-modifying treatment option for Parkinson's disease.
Prothena Corporation plc (NASDAQ:PRTA) today announced promising results from the Phase IIb PADOVA study, which investigated prasinezumab in 586 individuals with early-stage Parkinson's disease. Participants were treated for at least 18 months while on stable symptomatic treatment. The study revealed that prasinezumab showed potential clinical benefit in slowing motor progression, with a hazard ratio (HR) of 0.84 [0.69-1.01] and a p-value of 0.0657. Although the primary endpoint did not reach statistical significance, the data pointed toward a meaningful effect, particularly in a pre-specified analysis of patients treated with levodopa, which accounted for 75% of the participants. In this subgroup, prasinezumab demonstrated a HR of 0.79 [0.63-0.99] with a nominal p-value of 0.0431.
Key Findings and Subgroup Analysis
The study also presented supplementary covariate-adjusted analyses, which further supported prasinezumab's potential benefits. For the overall population, the HR was 0.81 [0.67-0.98] with a nominal p-value of 0.0334, indicating a statistically significant effect. In the levodopa-treated subgroup, the HR was 0.76 [0.61-0.95], with a nominal p-value of 0.0175, reinforcing the potential of prasinezumab as a therapeutic option in this population.
In addition to these primary and subgroup analyses, the study observed consistent positive trends across several secondary and exploratory endpoints, further validating the potential of prasinezumab in modifying the course of Parkinson's disease. Importantly, the drug was well tolerated throughout the study, and no new safety concerns were identified, which underscores its favorable safety profile.
Impact on Future Clinical Development
The results of the Phase IIb PADOVA study, along with previous clinical findings, will provide critical insights for Prothena and its partner Roche as they plan future studies of prasinezumab. The data will inform decisions on study design, statistical analysis, and the evaluation of specific patient sub-groups. Prasinezumab is positioned as a potential first-in-class disease-modifying treatment for Parkinson's disease, an area where there is a significant unmet medical need.
Gene Kinney, Ph.D., President and Chief Executive Officer of Prothena, expressed optimism about the results, emphasizing that the study represents a crucial step toward offering a disease-modifying therapy to the millions of people living with Parkinson’s disease. “We are excited to continue collaborating with Roche and look forward to presenting the results at an upcoming medical conference,” Kinney stated. The companies are also committed to working closely with health authorities to determine the most appropriate regulatory path forward.
Ongoing Studies and Next Steps
In addition to the PADOVA study, the Phase II PASADENA and open-label extension studies will continue to explore the long-term effects of prasinezumab. Roche will further evaluate the data and collaborate with health authorities to determine the next steps in the development of prasinezumab. This ongoing research and collaboration offer hope for a new, effective treatment option for Parkinson’s disease patients in the future.
